|
Characteristics
|
Total cohort (N = 457)
|
Training cohort, (N = 275)
|
Validation cohort (N = 182)
|
P value
|
|---|
|
Age
|
|
≤ 65
|
205 (44.86%)
|
128 (46.55%)
|
77 (42.31%)
|
0.4262
|
|
> 65
|
252 (55.14%)
|
147 (53.45%)
|
105 (57.69%)
|
|
Gender
|
|
Female
|
221 (48.36%)
|
138 (50.18%)
|
83 (45.6%)
|
0.3882
|
|
Male
|
236 (51.64%)
|
137 (49.82%)
|
99 (54.4%)
|
|
Stage
|
|
Stages I–II
|
246 (53.83%)
|
144 (52.36%)
|
102 (56.04%)
|
0.3331
|
|
Stages III–IV
|
196 (42.89%)
|
124 (45.09%)
|
72 (39.56%)
|
|
Not available
|
15 (3.28%)
|
7 (2.55%)
|
8 (4.4%)
|
|
T
|
|
T1–2
|
89 (19.47%)
|
52 (18.91%)
|
37 (20.33%)
|
0.6735
|
|
T3–4
|
367 (80.31%)
|
222 (80.73%)
|
145 (79.67%)
|
|
Tis
|
1 (0.22%)
|
1 (0.36%)
|
0 (0%)
|
|
M
|
|
M0
|
326 (71.33%)
|
194 (70.55%)
|
132 (72.53%)
|
0.8493
|
|
M1
|
68 (14.88%)
|
43 (15.64%)
|
25 (13.74%)
|
|
MX/not available
|
63 (13.79%)
|
38 (13.82%)
|
25 (13.74%)
|
|
N
|
|
N0
|
261 (57.11%)
|
149 (54.18%)
|
112 (61.54%)
|
0.2282
|
|
N1–2
|
195 (42.67%)
|
125 (45.45%)
|
70 (38.46%)
|
|
NX
|
1 (0.22%)
|
1 (0.36%)
|
0 (0%)
|
